Menu

Report Library

All Reports
Datamonitor Healthcare Infectious Disease KOL Interviews

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in

December 01, 2017

Datamonitor Healthcare interviewed two experts on infectious disease based in the UK and US to gauge their views on currently available treatment options, pipeline drugs, and challenges with clinical trial design in infectious disease. The specific drugs discussed include Triumeq [GSK], Genvoya [GILD], Descovy [GILD], BIC/F/TAF [GILD], Symtuza [JNJ], Tivicay/Edurant [GSK], Tivicay/Epivir [GSK], Cabotegravir/rilprivine [GSK], Fostemsavir [GSK], and DOR/3TC/TDF [MRK]. The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Disease Group Covered: Infectious disease
Back to the top Back to the top